PDCD1 and esophageal squamous cell carcinoma: Immune checkpoint blockade, particularly targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) interactions, has shown encouraging efficacy in subsets of ESCC patients (Markar, 2022).